BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) reports the increasing role of microwave ablation featured at European Conference on Interventional Oncology (ECIO), held in Florence, Italy. BSD also introduced new MicroThermX ® Microwave Ablation System (MicroThermX ®) products at ECIO. ECIO is a comprehensive international meeting focused exclusively on the rapidly growing field of interventional oncology, a key market for BSD's microwave ablation products. Leading interventional oncology experts from over 60 countries attended the conference. Many of the presentations focused on the essential role of microwave ablation in the hospital setting.
During the conference, BSD featured the new MicroThermX ® tabletop configuration, the T2, to the international market. The T2 gives the customer the option of a light weight system that has the same advanced features as the MicroThermX ® cart configuration. BSD also announced the Company’s upcoming introduction of the short tip antenna, which is designed to provide more spherical ablations for smaller tumors. The ability to deliver more spherical ablations will increase the range of tumors the clinician can treat using MicroThermX ®. The success of the meeting reflected the dynamic growth of microwave ablation throughout the world.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the U.S. FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.